



# ADTHYZA

## C A R E S

patient support program

### Guaranteed Pricing

Home Delivery to All 50 States

Free Shipping with 90-Day Supply

All Patients are Eligible \*†‡

**PAY AS LITTLE AS \$1 per day\***

Please note that Adthyza® has not been reviewed by the FDA for safety or efficacy.

## Getting Adthyza is simple & easy

**Adthyza Cares** is a simple, convenient program that saves your patients time and money by allowing patients to get prescriptions delivered directly to them, and **no insurance** is required.

Once the prescription is processed, the medication will be delivered directly to the patient's home.

### Three simple steps is all it takes:



#### STEP 1: You

ePrescribe, call or fax in the prescription to Adthyza Cares at Truax Patient Services. NCPDP# 2431461  
NPI# 1700149069 Surescripts# 169851  
Phone: (844) 289-3981 - Fax: (218) 444-2267



#### STEP 2: Patient's Phone

The patients will receive a call from Truax letting them know they received their prescription and to arrange for payment. Also, patients may inquire about their prescription by calling 844-289-3981



#### STEP 3: Patient's Home

Adthyza will be delivered right to the patients door

### With Adthyza Cares, patients pay a guaranteed price for Adthyza\*†‡

Medication supply	Out-of-pocket cost (cash price)
30 days	<b>\$35</b> plus shipping
90 days	<b>\$90</b> free shipping

\*Cash-paying patients.

† Based on once-daily dosing

‡ The cash discount prices listed are not valid for use with any prescription drug benefit plan.

¶ Any patient may opt to take advantage of Azurity's cash-payment programs; patients must attest the claim is not being billed through insurance. Prescriptions for cash paying patients will be triaged to the Adthyza Cares Azurity Solutions Patient Direct Program, which is fulfilled by Truax Patient Services. You will receive a call from Truax Patient Services, or you may call 844-289-3981 to inquire about the prescription.

**Questions? Call 844-289-3981**

Please see Important Safety Information on next page, and complete Prescribing Information, including Boxed Warning for **ADTHYZA**.

Please note that Adthyza® has not been reviewed by the FDA for safety or efficacy.

## IMPORTANT SAFETY INFORMATION

### INDICATIONS:

- ADTHYZA® (thyroid tablets, USP) is a prescription medicine indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.
- ADTHYZA® is also indicated as a pituitary TSH suppressant in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer.

### WARNING

**DRUGS WITH THYROID HORMONE ACTIVITY, ALONE OR TOGETHER WITH OTHER THERAPEUTIC AGENTS, HAVE BEEN USED FOR THE TREATMENT OF OBESITY. IN EUTHYROID PATIENTS, DOSES WITHIN THE RANGE OF DAILY HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION. LARGER DOSES MAY PRODUCE SERIOUS OR EVEN LIFE-THREATENING MANIFESTATIONS OF TOXICITY, PARTICULARLY WHEN GIVEN IN ASSOCIATION WITH SYMPATHOMIMETIC AMINES SUCH AS THOSE USED FOR THEIR ANORECTIC EFFECTS.**

### CONTRAINDICATIONS:

ADTHYZA® is contraindicated in patients with uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any component of the product.

The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective. Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism.

### WARNINGS AND PRECAUTIONS:

Thyroid hormones should be used with great caution in circumstances where the integrity of the cardiovascular system is suspected. In the elderly and in patients with cardiovascular disease, ADTHYZA should be used with greater caution. In these patients, therapy should be initiated with low doses of ADTHYZA. When, in such patients, a euthyroid state can only be reached at the expense of an aggravation of the cardiovascular disease, thyroid hormone dosage should be reduced.

Thyroid hormone therapy in patients with concomitant diabetes mellitus or diabetes insipidus, or adrenal cortical insufficiency aggravates the intensity of their symptoms, and appropriate adjustments of the various therapeutic measures directed at these concomitant endocrine diseases are required. The therapy of myxedema coma requires simultaneous administration of glucocorticoids.

Hypothyroidism decreases, and hyperthyroidism increases the sensitivity to oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants, and the dosage of the latter agents should be adjusted on the basis of frequent prothrombin time determinations. In infants, excessive doses of thyroid hormone preparations may produce craniosynostosis.

### CARCINOGENESIS/MUTAGENESIS:

A reportedly apparent association between prolonged thyroid therapy and breast cancer has not been confirmed, and patients on thyroid for established indications should not discontinue therapy. No confirmatory long-term studies in animals have been performed to evaluate carcinogenic potential, mutagenicity, or impairment of fertility in either males or females.

### PREGNANCY AND LACTATION:

Thyroid replacement therapy for hypothyroid women should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated. Minimal amounts of thyroid hormones are excreted in human milk. However, caution should be exercised when the thyroid is administered to a nursing woman. Routine determinations of serum T4 and/or TSH are strongly advised in neonates in view of the deleterious effects of thyroid deficiency on growth and development.

### ADVERSE REACTIONS:

Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare.

Many drugs and some laboratory tests may alter the therapeutic response to ADTHYZA®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Patients on oral anticoagulants, insulin, and oral hypoglycemics should be monitored closely during the initiation of thyroid replacement therapy.

### DRUG INTERACTIONS:

- Oral Anticoagulants: Concomitant use of thyroid hormones with oral anticoagulants alters the sensitivity of oral anticoagulants.
- Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.
- Cholestyramine or Colestipol—Cholestyramine or colestipol binds both levothyroxine (T4) and liothyronine (T3) in the intestine, thus impairing the absorption of these thyroid hormones. Four to five hours should elapse between the administration of cholestyramine or colestipol and thyroid hormones.
- Estrogen, Oral Contraceptives—Estrogens tend to increase serum thyroxine-binding globulin (TBG). In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine (T4) may be decreased when estrogens are started, thus increasing thyroid requirements. Patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogen or estrogen-containing oral contraceptives are given.

For further information, please see accompanying complete Prescribing Information for **ADTHYZA®**.

To report **SUSPECTED ADVERSE REACTIONS**, contact, Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or to the FDA at [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

PP-ADZ-US-0034

**Adthyza Cares** is a patient support program powered by Azurity Pharmaceuticals, Inc. and Member of the Azurity Solutions Patient Direct Program



Administered by  
**Truax Patient Services**

Phone:  
**844-289-3981**

Fax:  
**218-444-2267**



© 2023 Azurity Pharmaceuticals, Inc. All rights reserved.  
All trademarks referred to herein are property of their respective owners.  
Product labeling, packaging, and imagery are for representation purposes only.  
PP-ADZ-US-0098